USFDA completes PAI at Aurobindo Pharma’s Unit VII in Telangana

05 Aug 2023 Evaluate

The United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at Aurobindo Pharma’s Unit VII, a Formulation Manufacturing facility situated at Jedcherla Mandal, Mahaboob Nagar District, Telangana, from July 28 to August 4, 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1192.90 11.70 (0.99%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×